FOLFOX4和XELOX两周方案用于进展期胃癌新辅助化疗的随机对照研究(英文)  

FOLFOX4 and XELOX Program as Neoadjuvant Chemotherapy Biweekly for Advanced Gastric Cancer:A Randomized Controlled Study

作　　者：崔文峰[1] 杨俊省[1] 张学彬[1] 寇晨光[1] 赵磊[1] 林惠忠[2] 

机构地区：[1]山东省青岛大学,山东青岛266071 [2]青岛市立医院,山东青岛266071

出　　处：《现代生物医学进展》2010年第2期305-307,共3页Progress in Modern Biomedicine

摘　　要：目的:观察FOLFOX4和XELOX新辅助化疗方案治疗局部进展期胃癌的疗效和毒副作用。方法:68例初治确诊为局部进展期胃癌的患者,随机分为两组,每组各34例,分别采用XELOX和FOLFOX4化疗方案行术前两个疗程的化疗治疗。结果:XELOX组总有效率为47.06%,FOLFOX4组总有效率为41.08%,两组间无显著性差异。不良反应方面,FOLFOX4组恶心、呕吐,白细胞减少和口腔黏膜炎发生率较高,而XELOX组手足综合症发生率较高。结论:XELOX方案作为胃癌新辅助化疗方案,疗效与FOLFOX4方案相似,但XELOX方案副作用较轻且均可控制,化疗时间短,对机体损伤小,易于接受,值得在临床工作中进一步研究和推广。Objective：To investigate the treatment efficacy and side effects of FOLFOX4 and XELOX as neoadjuvant chemotherapy in locally advanced gastric cancer. Methods：68 cases diagnosed to be locally advanced gastric cancer were randomly divided into two groups,34 cases of patients in each group. The chemotherapy treatment of XELOX and FOLFOX4 were used before the operations for two courses of treatment. Results：The total effective rate in Group XELOX is 47.06%,while it is 41.08% in Group FOLFOX4. The incidence of nausea,vomiting,neutropenia and Oral mucositis is higher in group FOLFOX4. The incidence of hand-foot syndrome is higher in group XELOX. Conclusion：The program XELOX as neoadjuvant chemotherapy in gastric cancer had the similar effecte with the program FOLFOX4. The program XELOX had less side effectswith short chemotherapy time,and its damage to the body is easy to accept.

关 键 词：进展期胃癌 新辅助化疗 希罗达 奥沙利铂 

分 类 号：R735.2[医药卫生—肿瘤]